News
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
ORLANDO – ASH has released the first of five new sets of sickle cell disease guidelines, with the first focusing on screening and management of...
News
APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefit
Adding adjuvant pertuzumab to trastuzumab plus chemotherapy for HER2+ early breast cancer shows ongoing benefit vs. placebo at 6 years in the...
News
Oral arginine emerges as potential adjuvant for vaso-occlusive crisis management
ORLANDO – Researchers called for a phase 3, multicenter clinical trial to further evaluate the treatment.
News
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
News
Certolizumab may reduce uveitis flares, axSpA disease activity
ATLANTA – Certolizumab pegol shows multiple benefits – and improved benefit with earlier treatment – for axial spondyloarthritis.
News
TULIP trials show clinical benefit of anifrolumab for SLE
ATLANTA – Anifrolumab was well tolerated and provided clinical benefit for moderate-to-severe SLE in the global, phase 3 TULIP-1 and -2 trials.
News
Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
ATLANTA – The selective JAK1 inhibitor upadacitinib had a rapid effect, with a clear difference emerging between the treatment and placebo groups...
News
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
News
Large population-based study underscores link between gout, CVD event risk
ATLANTA – The relationships between gout and fatal and nonfatal CVD events found in a large population-based health data linkage study in New...
News
SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
ATLANTA – Biologic-naive patients with PsA responded better to ixekizumab than to adalimumab for skin and joint symptoms, and at least as well...
News
COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
ATLANTA – Adding ixekizumab to conventional background medications significantly improved the signs and symptoms of nonradiographic axSpA in the...
News
Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA
ATLANTA – Elderly-onset RA patients have outcomes with bDMARDs similar to those of young-onset patients, but are less likely to receive them.
News
Weekly tocilizumab provides durable benefits for giant cell arteritis patients
ATLANTA – Tocilizumab’s effects in GCA patients proved durable in nearly half of the patients treated weekly during the GiACTA trial and its 2-...
News
B-cell-poor RA responds better to tocilizumab than to rituximab
ATLANTA – B-cell-poor RA patients responded better to tocilizumab than to rituximab in the randomized, phase 4 R4-RA trial, suggesting a potential...
News
Guselkumab improves psoriatic arthritis regardless of prior TNFi use
ATLANTA – Guselkumab, an anti-IL-23p19 monoclonal antibody, showed efficacy versus placebo for active PsA in both biologic-naive and TNFi-treated...